Read the latest WaveData articles, or search through our archive.

Follow us on LinkedIn to keep up to date with WaveData news, articles, insights and analysis

Please use complete words when searching…

Charles Joynson, WaveData MD, asks ‘Is Alendronate Tabs 70mg 4 as fragile as cut glass?’

Charles Joynson, WaveData MD, asks ‘Is Alendronate Tabs 70mg 4 as fragile as cut glass?’

Ever since Alendronate Tabs 70mg 4 was launched in the UK as a Generic back in March 2005 the Drug Tariff has closely followed the Pharmacy purchase price, leaving little room for profit for either Manufacturers, Wholesalers, Pharmacists or Dispensing Doctors.

In early 2022 the average market price for this product reached a low of £0.22 and stayed the same for three months. This probably made Manufacturers think realistically about the profit potential of this product. Prices stayed low until April of that year when they started rising, eventually reaching a high of £12.66 in August 2022.

read more
Charles Joynson, WaveData MD, asks, ‘If launched in the UK, how quickly might the price of Empagliflozin decay?’

Charles Joynson, WaveData MD, asks, ‘If launched in the UK, how quickly might the price of Empagliflozin decay?’

Since April 2025 the MHRA have granted 24 Marketing Authorisation Licenses for Empagliflozin Tablets (10mg and 25mg variants). However, we are currently in legal limbo as patents still exist on the Brand which prevent Generic launch.

We have seen that the Wholesale industry are gradually swapping over from using the Brand name on their price lists and invoices to using the Generic name. We also notice that some Wholesalers are including these products in the Generic price lists, we presume this is in preparation for a potential Generic launch.

read more
Charles Joynson asks, ‘Did DHSC shoot itself in the foot?’

Charles Joynson asks, ‘Did DHSC shoot itself in the foot?’

In late 2025 and early 2026 the English Drug Tariff declined to its lowest point for four strengths of Ramipril Capsules (£0.68 – £0.75).  This was a few months after the market prices of these products reached their lowest level (£0.26 – £0.34). More recently concessions of between £0.73 and £6.82 have been granted each month since January to help Pharmacies dispense.

read more
What will my brand be worth after LOE?

What will my brand be worth after LOE?

If your brand is approaching its loss of exclusivity you maybe starting to think about the launch of generics. You’ll be concerned with how long you can maintain margin and retain he brand. Is it worth brand equalising, and if so for how long? In these situations, it’s very useful to have price analogues to help you forecast, or at least make some intelligent guesses about what market prices will be like in the months and years after loss of exclusivity.

read more
Charles Joynson, WaveData MD, conducts a deep dive on Respiratory Brands and Parallel Imports.

Charles Joynson, WaveData MD, conducts a deep dive on Respiratory Brands and Parallel Imports.

The graph shows the average PI price for a group of respiratory products. Each of the branded products shown in the chart is heavily effected by parallel imports as they were the most commonly traded PI respiratory products in May 2026, and in the top 12 of all PI’d products in that month.

read more
Stop the Bounce……

Stop the Bounce……

Charles Joynson takes a look at the long term changes to the commercial behaviour of Gabapentin Caps 300mg 100

When Gabapentin Caps 300mg 100 were launched way back in December 2003 prices came down from over £40 to less than £10 in just three years. It could have been this shock to the product price that resulted in a series of four price bounces and shortages or it could’ve been the disruption to reimbursement with the English Drug Tariff going up and down like a yo-yo in the early years. Whether it was both of these causes or just one, the erratic behaviour of the English Drug Tariff would not have helped.

read more
Charles Joynson, WaveData MD undertakes some analysis on short dated products.

Charles Joynson, WaveData MD undertakes some analysis on short dated products.

When a product is in seriously short supply, Pharmacies will get their hands on any stock they can to satisfy their customers. This sometimes means that they have to get short dated stock. If they have no long dated alternative, short dated will have to do. The presence of short dated stock in the market gives us a clue about the availability or shortage of that particular product.

read more
Concessions granted by year and by category

Concessions granted by year and by category

Here at WaveData we keep a close eye on the number of concessions granted to individual products each month and have been doing so since they were launched in November 2010. We have always assumed the Category M is the primary source of concessions and of the linked shortages, but this month Charles Joynson, WaveData MD, has taken a closer look to see if this is correct.

read more